Video
Dr. Chauhan on Key Recent Advances in Neuroendocrine Tumors
Author(s):
Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.
Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors (NETs), and points to the future with ongoing combination studies.
Advances across oncology over recent years are finally beginning to trickle down into more rare tumor types, such as NETs, which generally lag behind in drug developments, Chauhan explains. More clinical trials are being conducted in NETs as well, he added.
Two examples of such studies include combination studies that Chauhan is an investigator of. These include a phase 2 study that is evaluating the combination of telotristat ethyl (Xermelo) and Lutathera (lutetium Lu 177 dotatate) in patients with well-differentiated NETs. Moreover, Chauhan is also excited about a phase 1 trial of triapine and Lutathera combined as a treatment for patients with well-differentiated somatostatin receptor-positive gastroenteropancreatic NETs.
